FeesSafety
Pluang+

Hyperliquid hits $713M revenue from trading fees, eyes tokenized stocks for growth

Protocol Fundamentals
03 Nov 2026, 12:26 WIB
Crypto Briefing
View Source
Bullish
Hyperliquid hits $713M revenue from trading fees, eyes tokenized stocks for growth

Hyperliquid, a decentralized perpetual futures exchange, earned about $713 million in revenue over the past year mainly from trading fees. The platform operates on its own blockchain and uses fees to buy back and burn its native token, HYPE. Founder Jeff Yan is now focusing on expanding into tokenized real-world assets like large-cap stocks, with markets for Nvidia, Tesla, and Apple launching in October 2026. While the exchange has no external venture funding, growth in third-party markets could affect the revenue share that supports token buybacks, making future performance dependent on trading volume and market dynamics.

The story on Hyperliquid's $713 million revenue over the past year provides context for readers interested in digital asset markets. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Nov 03, 2026 16:41 WIB: out of 50 priced major cryptocurrencies tradable on Pluang, 7 rose and 42 fell today. Notable movers include CAKE (PancakeSwap) at Rp32.995 with a 1-day change of -5.52% and Pluang order activity of 92% Sell / 8% Buy, BAT (Basic Attention Token) at Rp2.275 with a 1-day change of -5.08% and Pluang order activity of 5% Sell / 95% Buy, and MANA (Decentraland) at Rp1.285 with a 1-day change of -4.32% and Pluang order activity of 98% Sell / 2% Buy.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App